Sprycel Dose Reduction To Be Considered By Oncology Cmte. During ASCO Road Show
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Oncologic Drugs Advisory Committee will review Bristol-Myers Squibb’s data package for the Gleevec-resistant leukemia therapy dasatinib on June 2.